David Hyman Acquires 20,000 Shares of Medicenna Therapeutics Corp. (TSE:MDNA) Stock

Medicenna Therapeutics Corp. (TSE:MDNA) Senior Officer David Hyman acquired 20,000 shares of Medicenna Therapeutics stock in a transaction dated Thursday, January 9th. The stock was bought at an average price of C$1.45 per share, for a total transaction of C$29,000.00.

Medicenna Therapeutics Trading Down 0.7 %

Shares of Medicenna Therapeutics stock traded down C$0.01 during mid-day trading on Friday, hitting C$1.44. 48,584 shares of the stock were exchanged, compared to its average volume of 64,551. The company has a 50-day simple moving average of C$1.80 and a 200 day simple moving average of C$2.01. The company has a current ratio of 2.51, a quick ratio of 4.65 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of C$110.06 million, a price-to-earnings ratio of -3.79 and a beta of 1.21. Medicenna Therapeutics Corp. has a twelve month low of C$0.40 and a twelve month high of C$2.98.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.